{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:13:32Z","timestamp":1790878412992,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To determine, using testicular germ cell cancer screening as an example, whether screening can also be effective for cancers with a good prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Based on the Dutch incidence, stage distribution, and survival and mortality data of testicular germ cell cancer, we developed a microsimulation model. This model simulates screening scenarios varying in screening age, interval, self\u2010examination or screening by the general practitioner (GP), and screening of a defined high\u2010risk group (cryptorchidism). For each scenario, the number of clinically and screen\u2010detected cancers by stage, referrals, testicular germ cell cancer deaths, and life\u2010years gained were projected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Annual self\u2010examination from age 20 to 30\u00a0years resulted in 767 cancers detected per 100,000 men followed over life\u2010time, of which 123 (16%) by screening. In this scenario, 19.2 men died from the disease, 4.7 (20%) less than without screening, and 230 life\u2010years were gained. Around 14,000 visits to the GP and 2080 visits to an urologist were required. This scenario resulted in the most favorable ratio between extra visits to the GP or urologist and deaths prevented (1418 and 116 respectively). Monthly screening, or screening until age 40 resulted in less favorable ratios. Self\u2010examination by only the high\u2010risk population prevented 1.0 death per 100,00 men in the general population. In all scenarios, 46\u201350 life\u2010years were gained for each testicular germ cell cancer death prevented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the good prognosis, self\u2010examination at young ages for testicular germ cell cancer could be considered.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3837","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T10:06:07Z","timestamp":1615543567000},"page":"2897-2903","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Screening for cancers with a good prognosis: The case of testicular germ cell cancer"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4890-6069","authenticated-orcid":false,"given":"Eveline A. M.","family":"Heijnsdijk","sequence":"first","affiliation":[{"name":"Department of Public Health Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Supit","sequence":"additional","affiliation":[{"name":"Department of Public Health Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leendert H. J.","family":"Looijenga","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-3646","authenticated-orcid":false,"given":"Harry J.","family":"de Koning","sequence":"additional","affiliation":[{"name":"Department of Public Health Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1504363"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.3332"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10400"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.293"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.288"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0029-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-004-0398-8"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.06.003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2007.02.003"},{"key":"e_1_2_9_11_1","unstructured":"Cancer Stat Facts: Testicular Cancer. NIH.2020.https:\/\/seer.cancer.gov\/statfacts\/html\/testis.html. Accessed June 24 2020"},{"key":"e_1_2_9_12_1","unstructured":"Globocan.http:\/\/globocan.iarc.fr. Accessed June 24 2020."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-6-201009210-00007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.318"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2016.04.006"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988318768597"},{"key":"e_1_2_9_17_1","article-title":"Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model","volume":"344","author":"Kok IM","year":"2012","journal-title":"BMJ"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju366"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29572"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2263"},{"key":"e_1_2_9_21_1","unstructured":"NKR cijfers. IKNL 2020.www.iknl.nl. Accessed June 22 2020."},{"key":"e_1_2_9_22_1","unstructured":"The Human Mortality Database. 2020 at mortality.org"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16400"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:14:27Z","timestamp":1693563267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/cam4.3837"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3837","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2020-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}